A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH)
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf064 ↗Kurz gefasst
Mixed-Methods-Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Wenwen Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Oncologists, Physician-Patient Relations, Communication. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Despite significant attention in the media and oncology community about improved outcomes associated with immune checkpoint inhibitors (ICIs), there remains a gap in our understanding of how oncologists describe ICIs to their patients. Communication around ICIs represents a challenge as some patients have durable, remarkable benefits while others experience severe toxicities. We investigated oncologist-patient communication practices by performing a mixed-methods study of in-clinic discussions about ICIs. Materials and Methods This was a mixed-method study in which in-clinic conversations between oncologists and their patients with advanced cancers about ICIs as potential treatments were audio-recorded. Patients were asked to complete a post-discussion survey. Qualitative data was derived from a general inductive thematic approach while descriptive statistics were used to analyze the survey responses.
Results
We recorded and analyzed 13 in-clinic conversations involving 8 oncologists and 13 patients. Twelve patients completed the post-discussion surveys. The conversations involved sophisticated discussions of immune function, cancer and ICI mechanisms, and trade-offs between anticancer benefits and toxicities. Oncologists incorporated metaphors and probabilistic information in their explanations. In the post-discussion surveys, patients indicated a preference for detailed information about ICIs and reported that they received the right depth of information in these discussions.
Conclusions
During in-clinic discussions of ICI therapy, oncologists provided detailed information about immunology and cancer, often aided by metaphors. Probabilities were commonly used to describe the likelihood of toxicities and benefits. The amount of information provided by the oncologists aligned with the patients' preference for detailed information about their cancer treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA.
- Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA, USA.
ORCID-Profile: Wenwen Chen, Evan T Hall
Zitieren
APA
Chen, W., Majovski, J., Bhatia, S., Chan, A., Grivas, P., Lee, S., Shah, S., Thompson, J. A., Tykodi, S. S., Veatch, J. R., Schapira, L., & Hall, E. T. (2025). A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH). The Oncologist. https://doi.org/10.1093/oncolo/oyaf064
Vancouver
Chen W, Majovski J, Bhatia S, Chan A, Grivas P, Lee S, et al. A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH). The Oncologist. 2025. doi:10.1093/oncolo/oyaf064
BibTeX
@article{Chen2025,
author = {Chen, Wenwen and Majovski, Julia and Bhatia, Shailender and Chan, Anissa and Grivas, Petros and Lee, Sylvia and Shah, Sumit and Thompson, John A and Tykodi, Scott S and Veatch, Joshua R and Schapira, Lidia and Hall, Evan T},
title = {A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH)},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf064}
}
EUVIMED